Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Outpatient Claims Data Could Be Released By June 1, AdvaMed Says

This article was originally published in The Gray Sheet

Executive Summary

AdvaMed remains hopeful that the Centers for Medicare & Medicaid Services will release the fiscal 2001 outpatient prospective payment system (OPPS) claims data by June 1, roughly one month prior to publication of the FY 2003 proposed rule

You may also be interested in...



OPPS Data Release Reverses Scully’s Earlier Stance; AdvaMed “Appreciative”

CMS will release its outpatient prospective payment system 2001 claims data to the public, a decision that represents a victory for industry stakeholders eager to examine the methodology that will be used to calculate the 2003 OPPS update

Concurrent CMS/FDA Review Is “The Real Issue,” Not OPPS Data – Scully

AdvaMed is hoping to assist the Centers for Medicare & Medicaid Services as the agency devises its 2003 outpatient prospective payment system (OPPS) update, but will be forced to do so without the benefit of analyzing data from years past

Prestige Expands UK Eye Care Range In Response To Consumer Demand

A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel